25 Feb 2019 – Edison Investment Research publish Research Note on Destiny Pharma entitled “Prevention is commercially cost effective”

Edison Investment Research Limited today published a Research Note on Destiny Pharma by Analyst Andy Smith entitled “Prevention is commercially cost effective”.  The research can be found here and the Destiny Pharma page on Edison’s website can be found here.